Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
SLO
Login
Search
Browsing
Upload document
Statistics
RUP
FAMNIT - Faculty of Mathematics, Science and Information Technologies
FHŠ - Faculty of Humanities
FM - Faculty of Management
FTŠ Turistica - Turistica – College of Tourism Portorož
FVZ - Faculty of Health Sciences
IAM - Andrej Marušič Institute
PEF - Faculty of Education
UPR - University of Primorska
ZUP - University of Primorska Press
COBISS
University of Primorska, University Library - all departments
First page
/
Show document
Show document
A-
|
A+
|
Print
Title:
Proizvodnja novega izdelka
Authors:
ID
Svoljšak, Aleš
(Author)
ID
Janeš, Aleksander
(Mentor)
More about this mentor...
Files:
Svoljsak_Ales_20110221.pdf
(1016,24 KB)
MD5: 0C33B83FD00E649154BB7B2569DC1F44
http://www.ediplome.fm-kp.si/Svoljsak_Ales_20110221.pdf
Language:
Slovenian
Work type:
Undergraduate thesis
Typology:
2.11 - Undergraduate Thesis
Organization:
FM - Faculty of Management
Keywords:
management
,
izdelki
,
cene
,
politika
,
načrtovanje
,
strategije
,
oskrbovalne verige
,
kakovost
Place of publishing:
Koper
Publisher:
[A. Svoljšak]
Year of publishing:
2011
Number of pages:
VI, 45 str. + pril
PID:
20.500.12556/RUP-2598
UDC:
658.5(043.2)
COBISS.SI-ID:
3869143
Publication date in RUP:
15.10.2013
Views:
11367
Downloads:
162
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
SVOLJŠAK, Aleš, 2011,
Proizvodnja novega izdelka
[online]. Bachelor’s thesis. Koper : A. Svoljšak. [Accessed 2 April 2025]. Retrieved from: https://repozitorij.upr.si/IzpisGradiva.php?lang=eng&id=2598
Copy citation
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:
Voting is allowed only for
logged in
users.
Share:
Similar works from our repository:
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
Similar works from other repositories:
Vpliv izražanja receptorja za inzulinu podoben rastni dejavnik 1 (IGF1R) na preživetje pri razsejanem nedrobnoceličnem raku pljuč
Uravnavanje izražanja genov z načrtovanimi transkripcijskimi dejavniki, odvisnimi od kalcijevih ionov
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.
Comments
Leave comment
You must
log in
to leave a comment.
Comments (0)
0 - 0 / 0
There are no comments!
Back